Literature DB >> 11931350

Synaptic proteins in Alzheimer's disease.

Josef Marksteiner1, Walter A Kaufmann, Peter Gurka, Christian Humpel.   

Abstract

Chromogranin A, chromogranin B, and secretogranin II are acidic proteins which are stored in large dense core vesicles of neurons. An antiserum, raised against a synthetic peptide (PE-11), present in the chromogranin B molecule, and an antiserum raised against secretoneurin contained in the secretogranin II sequence, was used to localize these peptides together with chromogranin A in the human hippocampal formation. The distribution of these peptides was investigated in Alzheimer's disease and compared to control subjects. Chromogranin A, chromogranin B, and secretogranin II are distinctly distributed with an overlap in their distribution patterns. They were only detected in neuronal structures. The highest density of immunoreactivity was found for chromogranin B. A layer specific distribution was especially obvious in the inner molecular layer of the dentate gyrus as secretoneurin-like immunoreactivity was restricted to its innermost part whereas that of chromogranin B was highly concentrated throughout the inner molecular layer. In Alzheimer's disease, about 10 to 20% of the amyloid-immunoreactive plaques contained either chromogranin A, chromogranin B or secretoneurin. The density of secretoneurin-and chromogranin B-like immunoreactivity was significantly reduced in the inner molecular layer of the dentate gyyrs, the CA1 area, the subiculum and in layers I, III and V of the entorhinal cortex. The present study demonstrates that chromogranin peptides are markers for human hippocampal pathways. Thee are particularly suitable to study nerve fibers, terminating at the inner molecular layer of the dentate gyrus. Chromogranin peptides have a potential as neuronal markers for synaptic degeneration in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11931350     DOI: 10.1385/JMN:18:1-2:53

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  35 in total

1.  PE-11, a peptide derived from chromogranin B, in the human brain.

Authors:  J Marksteiner; R Bauer; W A Kaufmann; E Weiss; U Barnas; H Maier
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

2.  Synaptic pathology in Alzheimer's disease: immunological data for markers of synaptic and large dense-core vesicles.

Authors:  H Lassmann; R Weiler; P Fischer; C Bancher; K Jellinger; E Floor; W Danielczyk; F Seitelberger; H Winkler
Journal:  Neuroscience       Date:  1992       Impact factor: 3.590

3.  The primary structure of rat secretogranin II deduced from a cDNA sequence.

Authors:  H H Gerdes; E Phillips; W B Huttner
Journal:  Nucleic Acids Res       Date:  1988-12-23       Impact factor: 16.971

4.  Distribution of secretoneurin, a peptide derived from secretogranin II, in rat brain: an immunocytochemical and radioimmunological study.

Authors:  J Marksteiner; R Kirchmair; S K Mahata; M Mahata; R Fischer-Colbrie; R Hogue-Angeletti; A Saria; H Winkler
Journal:  Neuroscience       Date:  1993-06       Impact factor: 3.590

Review 5.  Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization.

Authors:  T Arendt
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

6.  Secretoneurin--a neuropeptide generated in brain, adrenal medulla and other endocrine tissues by proteolytic processing of secretogranin II (chromogranin C).

Authors:  R Kirchmair; R Hogue-Angeletti; J Gutierrez; R Fischer-Colbrie; H Winkler
Journal:  Neuroscience       Date:  1993-03       Impact factor: 3.590

7.  Chromogranin immunoreactivity in the central nervous system. Immunochemical characterisation, distribution and relationship to catecholamine and enkephalin pathways.

Authors:  P Somogyi; A J Hodgson; R W DePotter; R Fischer-Colbrie; M Schober; H Winkler; I W Chubb
Journal:  Brain Res       Date:  1984-12       Impact factor: 3.252

8.  The Global Deterioration Scale for assessment of primary degenerative dementia.

Authors:  B Reisberg; S H Ferris; M J de Leon; T Crook
Journal:  Am J Psychiatry       Date:  1982-09       Impact factor: 18.112

9.  The distribution of chromogranin A-like immunoreactivity in the human hippocampus coincides with the pattern of resistance to epilepsy-induced neuronal damage.

Authors:  D G Munoz
Journal:  Ann Neurol       Date:  1990-03       Impact factor: 10.422

Review 10.  The chromogranins A and B: the first 25 years and future perspectives.

Authors:  H Winkler; R Fischer-Colbrie
Journal:  Neuroscience       Date:  1992-08       Impact factor: 3.590

View more
  21 in total

1.  Entorhinal verrucae geometry is coincident and correlates with Alzheimer's lesions: a combined neuropathology and high-resolution ex vivo MRI analysis.

Authors:  Jean C Augustinack; Kristen E Huber; Gheorghe M Postelnicu; Sita Kakunoori; Ruopeng Wang; André J W van der Kouwe; Lawrence L Wald; Thor D Stein; Matthew P Frosch; Bruce Fischl
Journal:  Acta Neuropathol       Date:  2011-12-13       Impact factor: 17.088

2.  Common functional genetic variants in catecholamine storage vesicle protein promoter motifs interact to trigger systemic hypertension.

Authors:  Kuixing Zhang; Fangwen Rao; Lei Wang; Brinda K Rana; Sajalendu Ghosh; Manjula Mahata; Rany M Salem; Juan L Rodriguez-Flores; Maple M Fung; Jill Waalen; Bamidele Tayo; Laurent Taupenot; Sushil K Mahata; Daniel T O'Connor
Journal:  J Am Coll Cardiol       Date:  2010-04-06       Impact factor: 24.094

Review 3.  Is synaptic loss a unique hallmark of Alzheimer's disease?

Authors:  Stephen W Scheff; Janna H Neltner; Peter T Nelson
Journal:  Biochem Pharmacol       Date:  2014-01-09       Impact factor: 5.858

Review 4.  Amyloid beta peptides, locus coeruleus-norepinephrine system and dense core vesicles.

Authors:  Jennifer A Ross; Beverly A S Reyes; Elisabeth J Van Bockstaele
Journal:  Brain Res       Date:  2018-03-22       Impact factor: 3.252

Review 5.  Chromogranin peptides in brain diseases.

Authors:  Michael Willis; Irmgard Leitner; Kurt A Jellinger; Josef Marksteiner
Journal:  J Neural Transm (Vienna)       Date:  2011-04-30       Impact factor: 3.575

Review 6.  Synaptic Dysfunction in Alzheimer's Disease: Aβ, Tau, and Epigenetic Alterations.

Authors:  Ke Li; Qing Wei; Fang-Fang Liu; Fan Hu; Ao-Ji Xie; Ling-Qiang Zhu; Dan Liu
Journal:  Mol Neurobiol       Date:  2017-04-29       Impact factor: 5.590

7.  Secretoneurin promotes neuroprotection and neuronal plasticity via the Jak2/Stat3 pathway in murine models of stroke.

Authors:  Woei-Cherng Shyu; Shinn-Zong Lin; Ming-Fu Chiang; Der-Cherng Chen; Ching-Yuan Su; Hsiao-Jung Wang; Ren-Shyan Liu; Chang-Hai Tsai; Hung Li
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

8.  Chromogranin B: intra- and extra-cellular mechanisms to regulate catecholamine storage and release, in catecholaminergic cells and organisms.

Authors:  Kuixing Zhang; Nilima Biswas; Jiaur R Gayen; Jose Pablo Miramontes-Gonzalez; C Makena Hightower; Maja Mustapic; Manjula Mahata; Chun-Teng Huang; Vivian Y Hook; Sushil K Mahata; Sucheta Vaingankar; Daniel T O'Connor
Journal:  J Neurochem       Date:  2013-11-25       Impact factor: 5.372

Review 9.  Cycles of aberrant synaptic sprouting and neurodegeneration in Alzheimer's and dementia with Lewy bodies.

Authors:  Makoto Hashimoto; Eliezer Masliah
Journal:  Neurochem Res       Date:  2003-11       Impact factor: 3.996

10.  Atomic view of an amyloid dodecamer exhibiting selective cellular toxic vulnerability in acute brain slices.

Authors:  Amber L H Gray; Michael R Sawaya; Debalina Acharyya; Jinchao Lou; Emery M Edington; Michael D Best; Rebecca A Prosser; David S Eisenberg; Thanh D Do
Journal:  Protein Sci       Date:  2022-01-05       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.